Genomic Health, Inc. (NASDAQ: GHDX) today announced worldwide commercial availability of its Oncotype DX colon cancer test, the first multigene ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE